201 related articles for article (PubMed ID: 30358175)
21. Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma.
Liu X; Wu T; Zhu SY; Shi M; Su H; Wang Y; He X; Xu LM; Yuan ZY; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Zhang YJ; Zhu Y; Cao JZ; Lan SM; Wu JX; Qi SN; Yang Y; Li YX
JAMA Netw Open; 2019 Mar; 2(3):e190194. PubMed ID: 30821826
[TBL] [Abstract][Full Text] [Related]
22. [Clinical differences between primary nasopharyngeal NK/T-cell lymphoma and primary nasal cavity NK/T-cell lymphoma with nasopharynx extension].
Liu WX; Liu YP; Jin J; Wang SL; Fang H; Ren H; Song YW; Chen B; Lu NN; Li N; Tang Y; Qi SN; Tang Y; Wang WH; Li YX
Zhonghua Zhong Liu Za Zhi; 2019 Jan; 41(1):56-62. PubMed ID: 30678418
[No Abstract] [Full Text] [Related]
23. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.
Wei W; Wu P; Li L; Zhang ZH
Hematology; 2017 Jul; 22(6):320-329. PubMed ID: 27917702
[TBL] [Abstract][Full Text] [Related]
24. Comparative Study of L-Asparaginase-Based LOP Regimen Over CHOP Regimen Before Radiotherapy for Stage IIE Extranodal Nasal Type NK/T Cell Lymphoma: A Study of 2 Centers.
Huang L; Yuan B; Wu H; Chu H; Liu Y; Wu S; Li H; Lu H; Chen H
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):152-158. PubMed ID: 28215935
[TBL] [Abstract][Full Text] [Related]
25. First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG.
Qi SN; Yang Y; Song YQ; Wang Y; He X; Hu C; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Qiao XY; Wang H; Li GF; Huang HQ; Zhang YJ; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Xu LM; Yuan ZY; Su H; Zhu J; Li YX
Blood Adv; 2020 Jul; 4(13):3141-3153. PubMed ID: 32658985
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of patients treated with SVILE
Wei L; Yang L; Ye J; Cong J; Li X; Yao N; Yang J; Cui X; Ding J; Wu Y; Wang J
Cancer Biol Med; 2020 Aug; 17(3):795-804. PubMed ID: 32944407
[No Abstract] [Full Text] [Related]
27. High-dose extended-field radiotherapy plus chemotherapy improved survival in extranodal NK/T-cell lymphoma in a real-life setting: results from the multicenter T-Cell Brazil Project.
de Pádua Covas Lage LA; Machado PPF; Reichert CO; Miranda E; Culler HF; da Siqueira SAC; de Oliveira Costa R; Miyashiro DR; Sanches JA; Rocha V; Chiattone CS; Pereira J
Sci Rep; 2022 Nov; 12(1):20557. PubMed ID: 36446856
[TBL] [Abstract][Full Text] [Related]
28. A five
Vittayawacharin P; Khuhapinant A
Hematology; 2021 Dec; 26(1):75-82. PubMed ID: 33427594
[TBL] [Abstract][Full Text] [Related]
29. Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy.
Zhang YP; Zhang R; Zhu HY; Wang L; Wu YJ; Liang JH; Shi WY; Liu H; Xu W; Li JY
Cancer Res Treat; 2019 Jan; 51(1):368-377. PubMed ID: 29764116
[TBL] [Abstract][Full Text] [Related]
30. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
[TBL] [Abstract][Full Text] [Related]
31. Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study.
Qi F; Wang WH; He XH; Chen B; Gui L; Fang H; Liu P; Wang SL; Yang JL; Song YW; Yang S; Qi SN; Zhou SY; Li YX; Dong M
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):61-70. PubMed ID: 30102205
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors and treatment outcomes for patients with stage II extranodal nasal-type natural killer/T-cell lymphoma of the upper aerodigestive tract.
Fang H; Jin J; Wang WH; Wang SL; Zhou LQ; Li YX
Leuk Lymphoma; 2014 Aug; 55(8):1832-7. PubMed ID: 24144309
[TBL] [Abstract][Full Text] [Related]
33. Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up.
Wang L; Wang WD; Xia ZJ; Zhang YJ; Xiang J; Lu Y
Med Oncol; 2014 Mar; 31(3):860. PubMed ID: 24481637
[TBL] [Abstract][Full Text] [Related]
34. Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study.
Wang H; Wuxiao ZJ; Zhu J; Wang Z; Wang KF; Li S; Chen X; Lu Y; Xia ZJ
Leuk Lymphoma; 2015 Apr; 56(4):971-7. PubMed ID: 24991715
[TBL] [Abstract][Full Text] [Related]
35. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study.
Yang Y; Zhu Y; Cao JZ; Zhang YJ; Xu LM; Yuan ZY; Wu JX; Wang W; Wu T; Lu B; Zhu SY; Qian LT; Zhang FQ; Hou XR; Li YX
Blood; 2015 Sep; 126(12):1424-32; quiz 1517. PubMed ID: 26109206
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerance of pegaspargase, gemcitabine and oxaliplatin with sandwiched radiotherapy in the treatment of newly-diagnosed extranodal nature killer (NK)/T cell lymphoma.
Jing XM; Zhang ZH; Wu P; Zhang SC; Ren YR; Xiong ZJ; Wei W; Luo L; Li L
Leuk Res; 2016 Aug; 47():26-31. PubMed ID: 27239738
[TBL] [Abstract][Full Text] [Related]
37. L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type.
Yong W; Zheng W; Zhu J; Zhang Y; Wang X; Xie Y; Lin N; Xu B; Lu A; Li J
Ann Hematol; 2009 Jul; 88(7):647-52. PubMed ID: 19107482
[TBL] [Abstract][Full Text] [Related]
38. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.
Lim SH; Hong JY; Lim ST; Hong H; Arnoud J; Zhao W; Yoon DH; Tang T; Cho J; Park S; Ko YH; Kim SJ; Suh C; Lin T; Kim WS
Ann Oncol; 2017 Sep; 28(9):2199-2205. PubMed ID: 28911074
[TBL] [Abstract][Full Text] [Related]
39. Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study.
Yang Y; Wang Y; Liu X; He X; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Qiao XY; Wang H; Li GF; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Xu LM; Su H; Song YQ; Zhu J; Zhang YJ; Huang HQ; Hu C; Qi SN; Li YX
Leukemia; 2021 Jun; 35(6):1671-1682. PubMed ID: 32943751
[TBL] [Abstract][Full Text] [Related]
40. CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase.
Yang J; Li P; Piao Y; Liu X; Wei L; Sang W; Zhang L; Wang L
Front Immunol; 2022; 13():829366. PubMed ID: 35371002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
